APA (7th ed.) Citation

JJ, C., AR, B., A, G., G, v. K., A, R., H, C., . . . S, S. (2026). Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia. American journal of hematology, 101(6), 1255. https://doi.org/10.1002/ajh.70285

Chicago Style (17th ed.) Citation

JJ, Castillo, et al. "Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia." American Journal of Hematology 101, no. 6 (2026): 1255. https://doi.org/10.1002/ajh.70285.

MLA (9th ed.) Citation

JJ, Castillo, et al. "Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia." American Journal of Hematology, vol. 101, no. 6, 2026, p. 1255, https://doi.org/10.1002/ajh.70285.